Brief: Longeveron announces constructive Type C meeting with U.S. FDA ahead of data readout for ELPIS II Phase 2b clinical trial evaluating treatment for Hypoplastic Left Heart Syndrome
08/05/2026 21:19
May 8 (Reuters) - Longeveron Inc LGVN.O: LONGEVERON ANNOUNCES CONSTRUCTIVE TYPE C MEETING WITH U.S. FDA AHEAD OF DATA READOUT FOR ELPIS II PHASE 2B CLINICAL TRIAL EVALUATING TREATMENT FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS) LONGEVERON INC - FDA NO LONGER REFERS TO ELPIS II TRIAL AS PIVOTAL LONGEVERON INC - FDA SAYS NEW PRIMARY ENDPOINT FOR ELPIS II CANNOT BE AGREED WHILE TRIAL ONGOING Source text: ID:nGNX9kkQlK Further company coverage: LGVN.O ((Reuters.Briefs@thomsonreuters.com;))